Review: Mayeux R and Sano M. Treatment of Alzheimer S Disease. NEJM 1999;341:1670-1679

 DEMENTIA

Review: Mayeux R and Sano M. Treatment of Alzheimer’s Disease. NEJM 1999;341:1670-1679.

Review: Schenk DB, Seubert P, Lieberburg I and Wallace J. B-Peptide Immunization, A Possible New Treatment for Alzheimer Disease. Arch Neurol 2000;57:934-936.

Review: Cummings, J. Cholinesterase Inhibitors: A New Class of Psychotropic Compounds. Am J Psychiatry 2000;157:4-15.

Review: Landes AM, Sperry SD, Strauss ME and Geldmacher DS. Apathy in Alzheimer’s Disease. JAGS 2001;49:1700-1707.

Review: Bullock, R. Drug Treatment in Dementia. Curr Opin Psychiatry 2001;14:349- 353.

Review: Clark C and Karlawish J. Alzheimer disease: Current concepts and emerging diagnostic and therapeutic strategies. Ann Int Med 2003;138:400-410.

Review: Khang P, Weintraub N and Espinoza R. The Use, Benefits, and Costs of Cholinesterase Inhibitors for Alzheimer’s Dementias in Long-Term Care: Are the Data Relevant and Reliable? JAMDA 2004;5:249-255.

Review: Cummings J. Alzheimer’s Disease. NEJM 2004;351:56-67.

Review: Weaver, J et al. The Utility of PET Brain Imaging in the Initial Evaluation of Dementia. JAMDA 2007;8:150-7.

Review: Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: Challenges to early intervention. Neurology 2007; 69: 1622-1634.

Review: Raina, P et al. Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline. Ann Int Med 2008;148:379-97.

Review: Qaseem A et al. Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Int Med 2008;148:370-8.

Review: Lee, M and Chodosh J. Dementia and life expectancy. What do we know? J Am Medical Directors Assoc, Sept, 2009;10:466-71. Folstein MF, Folstein SE and McHugh PR. “Mini-Mental State:” a Practical Method for Grading the Cognitive State of Patients for the Clinician. J Pyschiat Res 1975;12:189- 198.

Mega MS, Cummings JL, Fiorello T and Gornbein J. The Spectrum of Behavioral Changes in Alzheimer’s Disease. Neurology 1996;46:130-135.

Mega MS, Masterman DM, O’Connor SM, Barclay TR and Cummings JL. The Spectrum of Behavioral Responses to Cholinesterase Inhibitor Therapy in Alzheimer Disease. Arch Neurol 1999;56:1388-1393.

Mulnard RA, Cotman CW, Kawas C, et al. Estrogen Replacement Therapy for Treatment of Mild to Moderate Alzheimer Disease. JAMA 2000;283:1007-1015.

Jick H, Zornberg GL, Jick SS, Seshadri S and Drachman DA. Statins and the Risk of Dementia. Lancet 2000;356:1627-1631.

Morrison RS and Siu AL. Survival in End-Stage Dementia Following Acute Illness. JAMA 2000;284:47-52.

Masaki KH, Losonczy MA, Izmirlian G, et al. Association of Vitamin E and C Supplement Use with Cognitive Function and Dementia in Elderly Men. Neurology 2000;54:1265- 1272.

Doody R, Geldmacher D, Gordon B et al. Open-label, Multicenter, Phase 3 Extension Study of the Safety and Efficacy of Donezepil in Patients with Alzheimer Disease. Arch Neurol 2001;58:427-433.

Anthony JC, Breitner JCS, Zandi PP, et al. Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists. Neurology 2000;54:2066-2071. in ‘t Veld BA, Ruitenberg A, Hofman A, et al. Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer’s Disease. NEJM 2001;345:1515-1521.

Orgogozo J-M, Rigaud A-S, Stoffler A, Mobius H-J and Forette F. Efficacy and Safety of Memantine in Patients with Mild to Moderate Vascular Dementia: a Randomized, Placebo-Controlled Trial (MMM300). Stroke 2002;33:1834-1839.

Erkinjuntti T, Kurz S, Gauthier S Bullock R, Lillienfeld S and Damarju C. Efficacy of Galantamine in Probable Vascular Dementia and Alzheimer’s Disease Combined with Cerebrovascular Disease: a Randomised Trial. Lancet 359:1283-1290; 2002. Tariot PN, Farlow MR, Grossberg GT et al. Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil. JAMA 2004;291:317-324.

Schneider LS et al. Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer’s Disease. NEJM 2006;355:1525-38.

Mitchell SL et al. The Clinical Course of Advanced Dementia. NEJM 2009;361:1529-38.

Gill S at al. Syncope and Its Consequences in Patients with Dementia Receiving Cholinesterase Inhibitors. Arch Int Med 2009;169:867-873.

Sachs G et al. Cognitive Impairment: An Independent Predictor of Excess Mortality. Ann Int Med 2011;155:300-308.

Howard R et al. Donepezil and Memantine for Moderate-to-Severe Alzheimer’s Disease. NEJM 2012; 366:893-903.